In Brief: Wyeth-Ayerst Lodine XL
Executive Summary
Wyeth-Ayerst Lodine XL: Extended-release etodolac approved Oct. 25 for treatment of signs and symptoms of rheumatoid and osteoarthritis. The once-daily formulation of the non-steroidal anti-inflammatory became "approvable" on July 3; the NDA was filed in March 1995. Lodine XL will available in 400 mg and 600 mg tablets at an average wholesale price of $100 and $190, respectively, for 100-count bottles. The company says the price represents a 10% reduction in cost compared to regular Lodine therapy...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth